Biopharma

Biopharma Market Dynamics and Challenges

The current market conditions continue to exhibit an exciting rollercoaster from many biopharma companies. While FDA dynamics have been trending toward positive, there remains continuous pricing pressure from payers and patients. Despite what feels like an uncertain yet positive financing environment, early stage venture capital and later-stage private equity capital remain accessible for many companies as record amounts of funding continue to flow into the market in 2018.

Enter Locust Walk

For many emerging biopharma companies that need to raise capital via strategic partnerships or equity financings, we supplement a company’s C-suite or existing BD team with an expanded reach of capabilities, key contacts and long-standing relationships.

Locust Walk provides emerging biopharma companies with the strategic guidance and resources required to achieve their milestones and fulfill their potential. Since we don’t have the day-to-day pressures of managing a biopharma company, we can maintain a singular focus on helping to set strategy and then executing against the plan to deliver results for you regardless of the geographic focus of your deal.

Growth-oriented companies are often pursued as acquisition targets of other companies. Their best defense: Increasing scale and market valuation to stay beyond the reach of potential suitors and remain independent.  For those that ultimately are acquired, on clinical and commercial capabilities and pipeline can often increase deal value.  On the buy-side, most late-stage companies are looking to accelerate growth by bringing in additional clinical or commercial products.

Locust Walk is a market-maker with the ability to identify—uncovering overlooked assets—and transact target assets and companies across geographies, therapeutic areas, and modalities. Our comprehensive global footprint also enables the team to find assets wherever they reside.  Strategic deals and transactions can help enable a company to go public, get to a commercial stage more quickly, fill a critical pipeline gap, or simply add another product to a sales rep’s “bag” to complement existing marketed products.

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

Financing & IPO Advisory

OVERVIEW

  • Business case development
  • Targeted partner outreach
  • Due diligence staging
  • Deal structuring and evaluation
  • Contract negotiations

RESULTS

  • Data-driven approach
  • Structured process
  • Competitive tension and bidding
  • Real-time negotiations
  • Maximum deal value

OVERVIEW

  • Commercial assessment
  • Investor materials preparation
  • Targeted investor outreach
  • Due diligence staging
  • Deal comparables
  • Introductions to bankers and research analysts
  • S1 drafting (business section)

RESULTS

  • Robust understanding of opportunity
  • Succinct presentations
  • Relevant Investors
  • Competitive process
  • Realistic valuation and optimal outcome

Locust Walk offers a unique blend of exclusivity, superior deal flow, depth of expertise, and breadth of service for the growth biopharma sector.

Our international team of seasoned industry executives delivers specific, relevant operating deal experience. We provide comprehensive and exclusive guidance and support on both the buy-side and the sell-side.

Buy-side Process

Sell-side Process

OVERVIEW

  • Asset criteria development
  • Opportunity screening
  • Profile development
  • Target outreach
  • Due diligence
  • Deal structuring and evaluation
  • Contract negotiations

RESULTS

  • Strategic fit
  • Non-obvious opportunities
  • Timely decision-making
  • Transactability
  • Immediate increase in shareholder value

OVERVIEW

  • Business case development
  • Targeted partner outreach
  • Due diligence staging
  • Deal structuring and evaluation
  • Contract negotiations

RESULTS

  • Data-driven approach
  • Structured process
  • Competitive tension and bidding
  • Real-time negotiations
  • Maximum deal value

Locust Walk provides exciting new companies with the guidance and resources required to hit strategic growth benchmarks and fulfill their technological and market potential.

Our team’s deep industry experience enables us to help emerging biopharma firms scale up through rigorous assessment and analysis, connectivity with funding sources and strategic partners, and hands-on operational support.

Business & Corporate Development

OVERVIEW

  • Business case development
  • Targeted partner outreach
  • Due diligence staging
  • Deal structuring and evaluation
  • Contract negotiations

RESULTS

  • Data-driven approach
  • Structured process
  • Competitive tension and bidding
  • Real-time negotiations
  • Maximum deal value

Financing & IPO Advisory

OVERVIEW

  • Commercial assessment
  • Investor materials preparation
  • Targeted investor outreach
  • Due diligence staging
  • Deal comparables
  • Introductions to bankers and research analysts
  • S1 drafting (business section)

RESULTS

  • Robust understanding of opportunity
  • Succinct presentations
  • Relevant Investors
  • Competitive process
  • Realistic valuation and optimal outcome

Biopharma Transaction Highlights

THAR-LOGO-1-300x110

CLIENT: Thar Pharmaceuticals

TRANSACTION:
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition

View case study »

Stonebridge_Logo_Website

CLIENT: Strongbridge Biopharma

PARTNER: Investors

TRANSACTION:

Private Placement of $26.4M

View press release »

Locust_Fabrus_Senesco

CLIENT: Fabrus

PARTNER: Senesco

TRANSACTION:
Merger between Fabrus and Senesco Technologies

View case study »

Locust_Strategic

CLIENT: Strategic Science & Technologies, LLC

PARTNER: Undisclosed

TRANSACTION:
Worldwide Licensing Agreement for IbuCream (topical ibuprofen)

View case study »

CLIENT: Strongbridge Biopharma

PARTNER: Antisense Therapeutics

TRANSACTION:
Buy-side licensing agreement for ALT1103 for Acromegaly

View case study »

CLIENT: Strongbridge Biopharma

TRANSACTION:
Raised $25M in a U.S. initial public offering issuing 2,500,000 shares at $10 per share

View case study »

Locust_Strategic

CLIENT: Strategic Science & Technologies, LLC

PARTNER: Global OTC Player

TRANSACTION:
US Option Agreement for IbuCream (topical ibuprofen)

View case study »

Locust_Ascenta_Debiopharm

CLIENT: Ascenta

PARTNER: Debiopharm Group

TRANSACTION:
Worldwide Licensing Agreement for AT-406

View case study »

Locust_Concordian_Ono

CLIENT: Concordia Pharmaceuticals

PARTNER: Ono

TRANSACTION:
Licensing Agreement for Salirasib in Japan

View case study »

CLIENT: Strongbridge Biopharma

PARTNER: Aspireo Pharmaceuticals

TRANSACTION:
Buy-side product acquisition of Somatoprim for Acromegaly

View case study »

CLIENT: Strongbridge Biopharma

PARTNER: Investors

TRANSACTION:
Private Placement of $33.2M

View case study »

Locust_Teso_Aspen

CLIENT: TesoRx

PARTNER: Aspen

TRANSACTION:
Regional License Agreement and Investment for an Oral Unmodified Testosterone Replacement.

View case study »

Locust_Angio_Geron

CLIENT: Angiochem

PARTNER: Geron

TRANSACTION: Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase

View case study »

Locust_Otsuka_Proteus

CLIENT: Otsuka

PARTNER: Proteus

TRANSACTION:
$62.5 Million Follow on Financing

View case study »

Locust_Armetheon

CLIENT: Armetheon

PARTNER: Investors

TRANSACTION:
Series B Financing of 24M

View press release »

Locust_Armetheon

CLIENT: Armetheon

PARTNER: Investors

TRANSACTION:
Series A Financing of $7M

View press release »

Locust_Synthetic_Novartis

CLIENT: Synthetic Genomics

PARTNER: Novartis

TRANSACTION:
Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring

View case study »

Locust_Intermune_Vidara

CLIENT: InterMune

PARTNER: Vidara

TRANSACTION:
Actimmune Product Divestiture for $55M upfront plus 2 year royalty

View case study »